Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846042 | 0.75 | RHEB (0.36) | ACLYCDK4CCND1PLGPLAU | |
| SCHEMBL2184235 | 0.74 | ADRA2A (0.45) | ACLYCDK4CCND1 | |
| SCHEMBL6983245 | 0.70 | HTR7 (0.54) | ACLY | |
| SCHEMBL5790326 | 0.67 | CDK4 (0.43) | CDK4CCND1 | |
| SCHEMBL18708257 | 0.67 | HTR2A (0.53) | CDK4CCND1PLGPLAUMCL1 | |
| SCHEMBL29571527 | 0.65 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL2410943 | 0.65 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL4946004 | 0.64 | HSD11B1 (0.44) | — | |
| SCHEMBL19187614 | 0.64 | HTR2A (0.38) | ACLYMCL1HTR2AHTR2CKMO | |
| SCHEMBL5792293 | 0.64 | P2RX7 (0.53) | CDK4CCND1PLGPLAUHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| EP-1275647-B1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
| EP-1275647-A1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | ACLY 2375/4885KRAS 888/4885CDK4 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.